Mangaiarkarasi Asokan

List of Publications by Year
in descending order

24 papers	1,950 citations	516681 16 h-index	713444 21 g-index
25 all docs	25 docs citations	25 times ranked	3091 citing authors

#	Article	IF	Citations
1	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity, 2016, 45, 1108-1121.	14.3	304
2	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	28.9	270
3	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine, 2018, 24, 857-867.	30.7	256
4	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 2017, 358, 85-90.	12.6	225
5	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	3.4	205
6	Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications, 2015, 6, 8447.	12.8	88
7	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. Journal of Virology, 2015, 89, 12501-12512.	3.4	83
8	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity, 2017, 46, 777-791.e10.	14.3	81
9	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	14.3	77
10	Multiple NF-κB Sites in HIV-1 Subtype C Long Terminal Repeat Confer Superior Magnitude of Transcription and Thereby the Enhanced Viral Predominance. Journal of Biological Chemistry, 2012, 287, 44714-44735.	3.4	68
11	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology, 2016, 90, 5899-5914.	3.4	62
12	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18754-18763.	7.1	53
13	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Reports, 2018, 22, 1798-1809.	6.4	52
14	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
15	Improvement of antibody functionality by structure-guided paratope engraftment. Nature Communications, 2019, 10, 721.	12.8	27
16	Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. JCI Insight, 2021, 6, .	5.0	25
17	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports, 2022, 38, 110199.	6.4	19
18	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. MAbs, 2021, 13, 1946918.	5.2	11

#	Article	IF	Citations
19	Removal of variable domain <i>N</i>-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. MAbs, 2020, 12, 1836719.	5.2	4
20	Evident stabilization of the clinical profile in HIV/AIDS as evaluated in an open label clinical trial using a polyherbal formulation. Indian Journal of Medical Research, 2013, 137, 1128-44.	1.0	3
21	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. Journal of Clinical Investigation, 2021, 131, .	8.2	1
22	Attenuation of immune activation in an open-label clinical trial for HIV–AIDS using a polyherbal formulation. VirusDisease, 2014, 25, 302-313.	2.0	0
23	Potent Anti-Viral Activity of a Trispecific HIV Antibody in SHIV-Infected Monkeys. SSRN Electronic Journal, 0, , .	0.4	0
24	A Structure-Based Matrix Approach Yields Improved VRC01-Class Antibodies for HIV-1 Therapy and Prevention. SSRN Electronic Journal, 0, , .	0.4	0